Search results

The precision of Eupraxias DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal di

The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, also to be applicable in oncology, infectious disease and other critical disease areas. Eupraxia also recently completed a Phase 2b clinic

Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerabili

Senior Biopharmaceutical Statistician About Us: Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Eupraxia's EP-104GI is currently in a Phase 1b/2a t

Prior experience with supporting later stage regulatory filings including NDA or MAA. Please send your CV and cover letter to careers@eupraxiapharma. Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to addre

The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment

Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other

The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, also to be applicable in oncology, infectious disease and other critical disease areas. Eupraxia also recently completed a Phase 2b clinic

For further details about Eupraxia, please visit the Company's website at: We are looking for someone who would like to work for a fast-paced, growing company that fosters a creative spirit and integrated teamwork and is eligible to work in North America. Prior experience with supporting later st

For further details about Eupraxia, please visit the Company's website at: We are looking for someone who would like to work for a fast-paced, growing company that fosters a creative spirit and integrated teamwork and is eligible to work in North America. Prior experience with supporting later st